Toboroz
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Corinne Maurice Dror (principal investigator)
Toboroz
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jamie Feng (principal investigator)
Toboroz
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Jonathan M. Loree (principal investigator)
Toboroz
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Bernie (Bernhard) J. Eigl (principal investigator)
Toboroz
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
NCT05773274· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jonathan M. Loree (principal investigator)
Toboroz
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Stephen K. Chia (principal investigator)
Toboroz
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
NCT05451004· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Eric Tran (principal investigator)
Toboroz
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· 2/3. fázis· NRG Oncology· Forrás
Contact: Jonathan M. Loree (principal investigator)
Fut, nem toboroz
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
NCT04663997· 2. fázis· Canadian Cancer Trials Group· Forrás
Toboroz
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Alina S. Gerrie (principal investigator)
Toboroz
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Contact: EORTC HQ
Fut, nem toboroz
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
NCT04340141· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052· NRG Oncology· Forrás
Contact: Janice S. Kwon (principal investigator)
Fut, nem toboroz
A Study of miRNA 371 in Patients With Germ Cell Tumors
NCT04435756· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· 2/3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
NCT03768570· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457· 3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
NCT03822897· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
NCT03793179· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
NCT03550391· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Alan M. Nichol (principal investigator)
Fut, nem toboroz
Prostate Cancer Biomarker Enrichment and Treatment Selection
NCT03385655· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
NCT03113500· 2. fázis· City of Hope Medical Center· Forrás
Fut, nem toboroz
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
NCT03057106· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
NCT02503722· 1. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
NCT02520791· 1. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT02498613· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02506153· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
NCT02298959· 1. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02101775· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
NCT01841736· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
NCT01396408· 2. fázis· Canadian Cancer Trials Group· Forrás